Skip to main content

Select Drug Profiles

Pandemic Posting

David B. Nash, MD, MBA

David B. Nash, MD, MBA

Politics and Healthcare: Drug Pricing Dynamics Leading Up to the 2020 Election

Gary Branning, MBA, Kathryn Hayes, BA

Gary Branning, MBA; Kathryn Hayes, BA

Original Research, Practice Management

Economic Implications of Preventing Major Cardiovascular and Limb Events with Rivaroxaban plus Aspirin in Patients with Coronary or Peripheral Artery Disease in the United States

Luis Hernandez, MSc, MPH, Anshul Shah, BS Pharm, MS, Qi Zhao, MD, Dejan Milentijevic, PhD, MBA, Akshay Kharat, PhD

Luis Hernandez, MSc, MPH; Anshul Shah, BS Pharm, MS; Qi Zhao, MD; Dejan Milentijevic, PhD, MBA; Akshay Kharat, PhD

Original Research, Practice Management

Economic Burden of Neurologic Toxicities Associated with Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States

Michael S. Broder, MD, MSHS, Qiufei Ma, PhD, Tingjian Yan, PhD, Jie Zhang, PhD, Eunice Chang, PhD, David Kuzan, MD, Lamis Eldjerou, MD

Michael S. Broder, MD, MSHS; Qiufei Ma, PhD; Tingjian Yan, PhD; Jie Zhang, PhD; Eunice Chang, PhD; David Kuzan, MD; Lamis Eldjerou, MD

Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?

Karen Geary

Original Research, Practice Management, Neurology

A Retrospective Cost Analysis of Patients Who Switched from OnabotulinumtoxinA to IncobotulinumtoxinA in a Private Neurology Practice

Victoria K. Karschney, David R. Greeley, MD, FAAN

Victoria K. Karschney; David R. Greeley, MD, FAAN

Gavreto, RET Inhibitor, FDA Approved for Metastatic NSCLC with RET Fusions

Blenrep, First BCMA Antibody, Receives FDA Approval for Relapsed or Refractory Multiple Myeloma

FDA Approves Monjuvi for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Tecartus First CAR T-Cell Therapy FDA Approved for Patients with Mantle-Cell Lymphoma

Page 29 of 244
Results 281 - 290 of 2438